



OPEN TO ENROLLMENT

Clinical Trial of Everolimus in Children and Adolescents with *PTEN* Mutations



WHO

- Individuals ages 6-21 with a *PTEN* Mutation who meet a series of safety inclusion criteria

WHAT

- 6-month randomized controlled trial with everolimus (RAD001)
- Evaluate safety of everolimus and its potential to improve neurocognition

HOW

- Developmental Testing
- Safety Blood Tests
- Eye-tracking
- Electrophysiological Measures

For more information please contact **Robin Libove** at rlibove@stanford.edu.

The Developmental Synaptopathies Consortium (U54NS092090) is a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This consortium is funded through a collaboration between the NCATS, the NINDS and the NIMH.

